BR112016022342A2 - Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos - Google Patents

Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos

Info

Publication number
BR112016022342A2
BR112016022342A2 BR112016022342A BR112016022342A BR112016022342A2 BR 112016022342 A2 BR112016022342 A2 BR 112016022342A2 BR 112016022342 A BR112016022342 A BR 112016022342A BR 112016022342 A BR112016022342 A BR 112016022342A BR 112016022342 A2 BR112016022342 A2 BR 112016022342A2
Authority
BR
Brazil
Prior art keywords
indolizines
pyrimido
dihydro
derivatives
pharmaceutical compositions
Prior art date
Application number
BR112016022342A
Other languages
English (en)
Other versions
BR112016022342B1 (pt
BR112016022342A8 (pt
Inventor
Man Adrianus Petrus Antonius De
Rogier Christian Buijsman
Jan Gerard Sterrenburg
Joost Cornelis Marinus Uitdehaag
Wit Joeri Johannes Petrus De
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Publication of BR112016022342A2 publication Critical patent/BR112016022342A2/pt
Publication of BR112016022342A8 publication Critical patent/BR112016022342A8/pt
Publication of BR112016022342B1 publication Critical patent/BR112016022342B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016022342-0A 2014-04-07 2015-03-30 Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos BR112016022342B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207.4 2015-01-30
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
BR112016022342A2 true BR112016022342A2 (pt) 2017-08-15
BR112016022342A8 BR112016022342A8 (pt) 2021-07-20
BR112016022342B1 BR112016022342B1 (pt) 2022-10-04

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022342-0A BR112016022342B1 (pt) 2014-04-07 2015-03-30 Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos

Country Status (16)

Country Link
US (2) USRE48974E1 (pt)
EP (1) EP3129374B1 (pt)
JP (1) JP6518690B2 (pt)
KR (1) KR102432420B1 (pt)
CN (1) CN106132963B (pt)
AU (1) AU2015243694B2 (pt)
BR (1) BR112016022342B1 (pt)
CA (1) CA2944610C (pt)
DK (1) DK3129374T3 (pt)
ES (1) ES2716165T3 (pt)
HU (1) HUE043108T2 (pt)
MX (1) MX368767B (pt)
PL (1) PL3129374T3 (pt)
PT (1) PT3129374T (pt)
RU (1) RU2692479C2 (pt)
WO (1) WO2015155042A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283642B1 (en) * 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
US9771366B2 (en) * 2016-02-19 2017-09-26 Phoenix Molecular Design Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
PL3464272T3 (pl) 2016-06-07 2022-03-28 Jacobio Pharmaceuticals Co., Ltd. Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
MA49013A (fr) 2017-03-23 2021-05-05 Jacobio Pharmaceuticals Co Ltd Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
WO2023113479A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases
WO2023113477A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CA2526578C (en) 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ES2422299T3 (es) 2006-11-28 2013-09-10 Nerviano Medical Sciences Srl Indoles (4,5-dihidro) indoles tricíclicos
EP2303891B1 (en) * 2008-06-26 2016-02-17 Les Laboratoires Servier Pyrazolo-quinazolines as protein kinase activity modulators
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
JP5801285B2 (ja) 2009-04-29 2015-10-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害物質の塩
JP5851990B2 (ja) 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
RU2591191C2 (ru) * 2011-01-26 2016-07-10 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
AU2014302710B2 (en) 2013-06-24 2018-10-04 Merck Patent Gmbh Imidazole compounds as modulators of FSHR and uses thereof

Also Published As

Publication number Publication date
RU2016141405A (ru) 2018-05-07
KR102432420B1 (ko) 2022-08-17
PL3129374T3 (pl) 2019-07-31
BR112016022342B1 (pt) 2022-10-04
USRE48974E1 (en) 2022-03-15
AU2015243694B2 (en) 2019-01-17
HUE043108T2 (hu) 2019-07-29
EP3129374A1 (en) 2017-02-15
CN106132963B (zh) 2019-08-06
US9856258B2 (en) 2018-01-02
AU2015243694A1 (en) 2016-11-03
MX2016012997A (es) 2016-12-07
ES2716165T3 (es) 2019-06-10
CN106132963A (zh) 2016-11-16
RU2016141405A3 (pt) 2018-10-02
PT3129374T (pt) 2019-03-25
BR112016022342A8 (pt) 2021-07-20
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
MX368767B (es) 2019-10-15
EP3129374B1 (en) 2018-12-19
JP2017510595A (ja) 2017-04-13
KR20170013866A (ko) 2017-02-07
RU2692479C2 (ru) 2019-06-25
CA2944610C (en) 2024-01-09
CA2944610A1 (en) 2015-10-15
JP6518690B2 (ja) 2019-05-22
DK3129374T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
BR112016022342A2 (pt) Derivados de (5,6-di-hidro)pirimido[4,5-e] indolizinas, suas composições farmacêuticas, e seus usos
IL240877A0 (en) History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them
IL251441A0 (en) History of imidazo pyridine and pharmaceutical preparations containing them
IL250280B (en) Spiro[3h-indole-3, 2'-pyrrolidine]-2(1h)-one compounds, and their derivatives and pharmaceutical preparations containing them
EP3280715A4 (en) NOVEL 5 OR 8 SUBSTITUTED IMIDAZO [1,5-A] PYRIDINS AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
ZA201902562B (en) Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
DK3177627T3 (da) Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
FR22C1058I1 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
HK1225723A1 (zh) 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
HK1247203A1 (zh) 取代的咪唑並[1，2-α]吡啶-2-基胺化合物及其藥物組合物和使用方法
IL250267B (en) History of indolizine, their preparation and pharmaceutical preparations containing them
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
IL252254B (en) Anticancer drugs derived from 7-morpholinyl-2-n-piperazinyl-methyl thiano-[3,2-c]-pyridine
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
EP3190111A4 (en) Pyrazolo[3,4-c]pyridine derivatives
EP3371192A4 (en) PODOPHYL LOTOXIN DERIVATIVES AND THEIR USE
EP3143017A4 (en) Bicyclic derivatives and pharmaceutical composition including the same
EP3227292A4 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
BR112016020135A2 (pt) mistura de composto, seus usos, composição farmacêutica, e conjunto (kit)
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่
AU2014904868A0 (en) 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2015, OBSERVADAS AS CONDICOES LEGAIS